Taiho Pharmaceutical Co Ltd - Company Profile
Powered by 
All the data and insights you need on Taiho Pharmaceutical Co Ltd in one report.
$295
- Save hours of research time and resources with
our up-to-date Taiho Pharmaceutical Co Ltd Strategy Report
- Understand Taiho Pharmaceutical Co Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Taiho Pharmaceutical Co Ltd (Taiho), a subsidiary of Otsuka Group, develops and markets pharmaceutical products in the field of cancer, immunology, allergy and urology. Its product portfolio includes pharmaceutical products such as anti-allergic agents, anti-tumor agents, H2 receptor antagonists, antibiotics and medical devices; and consumer health products such as herbal digestive medicine, topical analgesics, antifungal cream and herbal medicine powder, among others. Taiho has production facilities in Tokushima, Saitama, Okayama, Kitajima and Inuyama. It operates through its subsidiaries situated worldwide including Japan, China, Canada, Singapore, the UK and the US. Taiho is headquartered in Tokyo, Japan.
Headquarters
Japan
Address
1-27 Kandanishiki, Chiyoda-ku, Tokyo, 101-8444
Website
www.taiho.co.jp
Telephone
81 3 32944527
No of Employees
2,170
Industry
Pharmaceuticals and Healthcare
Revenue (2022)
$7.8M
Taiho Pharmaceutical Co Ltd premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Anti-Allergy Drugs | Formulation Development | ZOSYN |
| Liver Disease Drugs | Chemistry, Manufacturing and Control | Lonsurf |
| Antipyretic and Analgesic Drugs | Abraxane | |
| XYZ | XYZ | |
| XYZ | XYZ | |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In November, the company entered into an agreement with Araris Biotech AG to create future ADC by applying Araris' unique linker conjugation science. |
| 2023 | New Products/Services | In April, the company received an U.S. Food and Drug Administration approval for priority review supplemental New Drug Application for the use of Trifluridine/Tipiracil (LONSURF) |
| 2022 | New Product Approvals | In October, the company entered into approval from U.S. FDA approves FGFR inhibitor, Futibatinib for the Treatment of Metastatic Intrahepatic Cholangiocarcinoma. |
Competitor Comparison
| Key Parameters | Taiho Pharmaceutical Co Ltd | Chugai Pharmaceutical Co Ltd | Nippon Shinyaku Co Ltd | Kissei Pharmaceutical Co Ltd | Kowa Co Ltd |
|---|---|---|---|---|---|
| Headquarters | Japan | Japan | Japan | Japan | Japan |
| City | Tokyo | Chuo-Ku | Kyoto-Shi | Matsumoto-Shi | Sakai-Shi |
| State/Province | Tokyo | Tokyo | Kyoto | Nagano | Osaka |
| No. of Employees | 2,170 | 7,771 | 2,186 | 1,795 | 7,865 |
| Entity Type | Private | Public | Public | Public | Public |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Masayuki Kobayashi | Director; President | Executive Board | - | - |
| Stephen Yoder | Vice President - Business Development, Taiho Oncology | Senior Management | 2020 | - |
| Atsushi Azuma | Director | Senior Management | - | - |
| Teruhiro Utsugi | Managing Director | Senior Management | - | - |
| Tatsuya Niki | Executive Director | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward